247 Wallst
27 Mar 2026, 13:56 UTC · 31w ago
Impact · against what's priced in
AstraZeneca sees a positive catalyst from unexpected clinical success in COPD, while cybersecurity firms face downward pressure from perceived AI disruption. Netflix and Tesla are seeing modest positive moves from price hikes and speculative merger talk, respectively.
No priced-in read yet
What the story claims
6 claims · scored −1 bearish … +1 bullish
Brent Crude is nearing $111 a barrel and WTI has topped $96 due to ongoing conflict in Iran and stalled traffic in the Strait of Hormuz.
More negative than 99% of claims this week
The 30-year Treasury yield has climbed to 4.986%, the highest level since September.
So whatHigher long-term yields suggest the market expects rates to remain elevated, which pressures equity valuations, especially for growth stocks.
Continue reading
5 related stories
Reports of Anthropic's 'Claude Mythos' model have sparked fears that AI could replace traditional cybersecurity tools, leading to a sell-off.
Read from the article alone
No priced-in read yet
The stock is trading lower as the market interprets the leak of Anthropic's new AI model as a threat to the necessity of traditional security tools.
Read from the article alone
No priced-in read yet
The success of Tozorakimab in two late-stage trials for COPD caught analysts off guard, representing a notable shift in sentiment for the company.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Anthropic is reportedly testing a new AI model, 'Claude Mythos,' which is perceived to pose unprecedented cybersecurity risks and potentially replace traditional security tools.
More negative than 91% of claims this week
AstraZeneca's experimental drug Tozorakimab succeeded in two late-stage clinical trials for chronic obstructive pulmonary disease.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Shares jumped 4% after a lung disease drug succeeded in two late-stage clinical trials.
More negative than 84% of ticker scores this week
Trading lower due to fears that new AI models from Anthropic may replace traditional cybersecurity tools.
More negative than 84% of ticker scores this week
Trading lower due to fears that new AI models from Anthropic may replace traditional cybersecurity tools.
More negative than 84% of ticker scores this week
Trading lower due to fears that new AI models from Anthropic may replace traditional cybersecurity tools.
More positive than 68% of ticker scores this week
Raising prices across all U.S. plans and receiving an Overweight rating from KeyBanc.
More positive than 64% of ticker scores this week
Positive speculation regarding a potential blockbuster merger with SpaceX.
More negative than 75% of ticker scores this week
Stock is down 3% amid broader market volatility and a downtrend.
More positive than 59% of ticker scores this week
Releasing new Gemini AI tools to make it easier for users to switch from competitors.
More negative than 70% of ticker scores this week
Stock is down 1.7% as tech stocks in the Dow struggle.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
12h ago
More positive than 34% of relationship scores this week
[mutual] Both are cybersecurity stocks trading lower due to perceived AI risks from Anthropic's new model.
More positive than 34% of relationship scores this week
[mutual] Both are cybersecurity stocks trading lower due to perceived AI risks from Anthropic's new model.
+68.1%
Price is moving against the score
$237.83 vs $141.50 close before publication (Mar 26) · not market-adjusted
ZS chart →+1.8%
Price agrees with the score
$186.65 vs $183.40 close before publication (Mar 26) · not market-adjusted
AZN chart →+155.1%
Price is moving against the score
$250.43 vs $98.16 close before publication (Mar 26) · not market-adjusted
CRWD chart →
